A five-year Master Services Agreement (MSA) has been signed between ViroCell Biologics and a prominent U.S. NCI-designated cancer center. This agreement provides the cancer center access to ViroCell’s comprehensive viral vector manufacturing services for preclinical and clinical applications.
ViroCell’s services include viral vector design, small-scale manufacturing, process development, and global plasmid sourcing. Clinical services encompass GMP manufacturing, quality control testing, regulatory support, and final batch approval.
This MSA builds upon ViroCell’s successful lentivirus vector production for the cancer center’s clinical evaluation of an engineered T cell receptor (TCR) therapy. The vector was delivered in less than five months, demonstrating ViroCell’s ability to provide high-quality vectors rapidly.
ViroCell’s expertise in viral vector manufacturing aims to support cutting-edge research in academia and industry. The company aims to accelerate the development of cell and gene therapies by providing specialized manufacturing services.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
